We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PAX:NASDAQPatria Investments Limited Analysis

Data as of 2026-06-13 - not real-time

$11.55

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Patria Investments (PAX) is trading at $11.55, which sits above the 20‑day SMA (11.34) but falls well short of the 50‑day (12.08) and 200‑day (13.89) averages, signaling a short‑term dip within a broader bearish trend. The RSI of 49.1 hovers just below the neutral 50 mark, while the MACD shows a modest bullish signal (histogram +0.059) despite a negative line‑to‑signal gap, hinting at a possible micro‑reversal. Volatility is high at 39 % (30‑day) and the stock’s beta of 1.21 exceeds the market, underscoring exposure to swings. Financially, the company posts a solid 22 % YoY revenue growth, 18 % profit margin and 58 % gross margin, yet its trailing P/E of 21.8 dwarfs the industry average of 16.8, suggesting overvaluation. The dividend yield of 5.3 % is attractive but the payout ratio exceeds 100 % (1.13) and cash flow is nil, flagging sustainability concerns.
The upcoming Q1‑2026 earnings release and an ex‑dividend date within days add short‑term focus, while a recent 24 % increase in insider stock by the senior managing partner signals confidence. However, the combination of high volatility, overvaluation and an unsustainable dividend temper enthusiasm, positioning PAX for cautious handling across all horizons.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • price below 50‑day/200‑day SMA
  • high 30‑day volatility (39 %)
  • bearish trend direction

Medium Term

1–3 years
Neutral
Model confidence: 8/10

Key Factors

  • 22 % revenue growth
  • upcoming Q1‑2026 earnings release
  • 24 % insider stock increase

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • stable asset‑management sector
  • forward P/E of 7.44 indicating potential re‑valuation
  • geographic diversification across Latin America, Europe and the US

Key Metrics & Analysis

Financial Health

Revenue Growth22.00%
Profit Margin18.10%
P/E Ratio21.8
ROE13.34%
ROA5.74%
Debt/Equity41.03
P/B Ratio3.0
Industry P/E16.8

Technical Analysis

TrendBearish
RSI49.1
Support$10.72
Resistance$11.83
MA 20$11.34
MA 50$12.08
MA 200$13.89
MACDBullish
VolumeStable
Fear & Greed Index89.86

Valuation

Target Price$15.57
Upside/Downside34.82%
GradeOvervalued
TypeBlend
Dividend Yield5.30%

Risk Assessment

Beta1.21
Volatility39.24%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.